Are We Overlooking the Use of Oral Ribavirin for Respiratory Syncytial Virus Infection Following Hematopoietic Stem Cell Transplantation?

ConclusionsOral RBV appears to be well tolerated, but its benefit in RSV infections remains unclear. Randomized controlled trials are needed to further evaluate its safety and efficacy at escalating doses in this patient population.
Source: Current Treatment Options in Infectious Diseases - Category: Infectious Diseases Source Type: research